Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shows promise in controlling advanced cancers

NCT ID NCT03400332

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approach, not a cure, as ongoing treatment is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

281 people

The number who actually took part.

Started

Feb 2018

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1 * At least 1 lesion accessible for biopsy * Eastern Cooperative Oncology Group Performance Status of 0 or 1 Exclusion Criteria: * Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll) * Participants with active, known or suspected autoimmune disease * Participants with conditions requiring systemic treatment with either corticosteroids (\> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration * Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS) * Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy Other protocol defined inclusion/exclusion criteria could apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Melanoma

Contacts and locations

Locations

  • Comprehensive Cancer Centers Of Nevada

    Las Vegas, Nevada, 89169, United States

  • Local Institution - 0001

    Pittsburgh, Pennsylvania, 15213, United States

  • Local Institution - 0002

    New York, New York, 10032, United States

  • Local Institution - 0003

    Lutherville, Maryland, 21093, United States

  • Local Institution - 0004

    Ann Arbor, Michigan, 48109, United States

  • Local Institution - 0005

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0006

    San Antonio, Texas, 78240, United States

  • Local Institution - 0007

    Lakewood, Colorado, 80228, United States

  • Local Institution - 0008

    Norfolk, Virginia, 23502, United States

  • Local Institution - 0009

    Greenville, South Carolina, 29615, United States

  • Local Institution - 0010

    Dallas, Texas, 75246, United States

  • Local Institution - 0011

    Austin, Texas, 78705, United States

  • Local Institution - 0012

    Columbia, Maryland, 21044, United States

  • Local Institution - 0013

    Tyler, Texas, 75702, United States

  • Local Institution - 0014

    Fort Worth, Texas, 76104-3927, United States

  • Local Institution - 0015

    Fairfax, Virginia, 22031, United States

  • Local Institution - 0017

    Eugene, Oregon, 97401, United States

  • Local Institution - 0018

    Houston, Texas, 77030, United States

  • Local Institution - 0019

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Local Institution - 0020

    Toronto, Ontario, M5G 1Z5, Canada

  • Local Institution - 0021

    Pamplona, 31008, Spain

  • Local Institution - 0022

    Madrid, 28040, Spain

  • Local Institution - 0023

    Madrid, 28050, Spain

  • Local Institution - 0024

    Manchester, Greater Manchester, M20 4BX, United Kingdom

  • Local Institution - 0025

    New York, New York, 10029, United States

  • Local Institution - 0026

    Rozzano-milano, 20089, Italy

  • Local Institution - 0027

    Naples, 80131, Italy

  • Local Institution - 0028

    Oklahoma City, Oklahoma, 73104, United States

  • Local Institution - 0029

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Local Institution - 0030

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0032

    New Brunswick, New Jersey, 08903, United States

  • Local Institution - 0034

    Berlin, 12200, Germany

  • Local Institution - 0036

    Ghent, 9000, Belgium

  • Local Institution - 0037

    Brussels, 1200, Belgium

  • Local Institution - 0039

    Zurich, 8091, Switzerland

  • Local Institution - 0040

    Lausanne, 1011, Switzerland

  • Local Institution - 0041

    Sankt Gallen, 9007, Switzerland

  • Local Institution - 0042

    Milan, 20132, Italy

  • Local Institution - 0043

    Forlì, 47014, Italy

  • Local Institution - 0044

    Málaga, 29010, Spain

  • Local Institution - 0045

    Madrid, 28034, Spain

  • Local Institution - 0047

    Santiago de Compostela, 15706, Spain

  • Local Institution - 0049

    Lund, 221 85, Sweden

  • Local Institution - 0052

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Local Institution - 0053

    Hamburg, 20251, Germany

  • Local Institution - 0054

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Local Institution - 0055

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0056

    Montreal, Quebec, H2X 0A9, Canada

  • Local Institution - 0058

    Salt Lake City, Utah, 84112, United States

  • Local Institution - 0059

    Springdale, Arkansas, 72762, United States

  • Local Institution - 0060

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0067

    Marseille, Bouches-du-Rhône, 13385, France

  • Local Institution - 0068

    Paris, 75010, France

  • Local Institution - 0069

    Villejuif, 94800, France

  • Local Institution - 0071

    Krakow, 31-115, Poland

  • Local Institution - 0076

    Omaha, Nebraska, 68130, United States

  • Local Institution - 0077

    Warsaw, 02-781, Poland

  • Local Institution - 0078

    Victoria, British Columbia, V8R 6V5, Canada

  • Local Institution - 0082

    Kortrijk, 8500, Belgium

  • Local Institution - 0083

    Glasgow, Lanarkshire, G12 0YN, United Kingdom

  • Local Institution - 0085

    Nantes, 44000, France

  • Local Institution - 0087

    Atlanta, Georgia, 30322, United States

  • Local Institution - 0088

    Wollstonecraft, New South Wales, 2065, Australia

  • Local Institution - 0090

    Melbourne, Victoria, 3000, Australia

  • Local Institution - 0091

    Ballarat Central, VIC 3350, Australia

  • Local Institution - 0095

    Melbourne, Victoria, 3004, Australia

  • Local Institution - 0096

    Adelaide, South Australia, 5000, Australia

  • Local Institution - 0097

    Perth, Western Australia, 6009, Australia

  • Local Institution - 0099

    Los Angeles, California, 90033, United States

  • Local Institution - 0100

    Atlanta, Georgia, 30342, United States

  • Local Institution - 0101

    Marietta, Georgia, 30060, United States

  • Local Institution - 0102

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.